RECURSION PHARMACEUTICALS, INC.: capital expenditure payments
Capital expenditure payments for RECURSION PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All RECURSION PHARMACEUTICALS, INC. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 6,469,000 | USD | 2026-02-25 | 10-K · 0001601830-26-000039 |
| 2024-01-01 | 2024-12-31 | 13,695,000 | USD | 2026-02-25 | 10-K · 0001601830-26-000039 |
| 2023-01-01 | 2023-12-31 | 11,955,000 | USD | 2026-02-25 | 10-K · 0001601830-26-000039 |
| 2022-01-01 | 2022-12-31 | 37,059,000 | USD | 2025-02-28 | 10-K · 0001601830-25-000035 |
| 2021-01-01 | 2021-12-31 | 39,798,000 | USD | 2024-02-29 | 10-K · 0001601830-24-000019 |
| 2020-01-01 | 2020-12-31 | 5,831,000 | USD | 2023-02-27 | 10-K · 0001601830-23-000010 |
| 2019-01-01 | 2019-12-31 | 3,910,000 | USD | 2022-03-23 | 10-K · 0001601830-22-000012 |
Related financial histories
- RECURSION PHARMACEUTICALS, INC.: total assets
- RECURSION PHARMACEUTICALS, INC.: total liabilities
- RECURSION PHARMACEUTICALS, INC.: stockholders equity
- RECURSION PHARMACEUTICALS, INC.: cash and cash equivalents
- RECURSION PHARMACEUTICALS, INC.: net income or loss
- RECURSION PHARMACEUTICALS, INC.: operating cash flow
- RECURSION PHARMACEUTICALS, INC.: contract revenue excluding tax
- RECURSION PHARMACEUTICALS, INC.: financing cash flow
- RECURSION PHARMACEUTICALS, INC.: investing cash flow
- RECURSION PHARMACEUTICALS, INC.: retained earnings or deficit
- RECURSION PHARMACEUTICALS, INC.: basic weighted-average shares
- RECURSION PHARMACEUTICALS, INC.: diluted weighted-average shares
- RECURSION PHARMACEUTICALS, INC.: basic earnings per share
- RECURSION PHARMACEUTICALS, INC.: diluted earnings per share
- RECURSION PHARMACEUTICALS, INC.: income tax expense or benefit
- RECURSION PHARMACEUTICALS, INC.: net property, plant and equipment
- RECURSION PHARMACEUTICALS, INC.: share-based compensation expense
- RECURSION PHARMACEUTICALS, INC.: operating income or loss
- RECURSION PHARMACEUTICALS, INC.: current assets
- RECURSION PHARMACEUTICALS, INC.: interest expense
- RECURSION PHARMACEUTICALS, INC.: current liabilities
- RECURSION PHARMACEUTICALS, INC.: current accounts payable
- RECURSION PHARMACEUTICALS, INC.: goodwill carrying amount
- RECURSION PHARMACEUTICALS, INC.: net finite-lived intangible assets
- RECURSION PHARMACEUTICALS, INC.: net current accounts receivable
- RECURSION PHARMACEUTICALS, INC.: operating expenses
- RECURSION PHARMACEUTICALS, INC.: research and development expense
Inspect the source
- Entity
- RECURSION PHARMACEUTICALS, INC. / CIK 0001601830
- Captured
- 2026-09-20T09:25:28.528Z
- SEC response SHA-256
238c834540b26747e7f8af5dc10e3b986fcfbc96383469c4a944c9a5b2844e04
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001601830.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))